Skip to main content
Erschienen in:

06.06.2024 | Case Report

Erdheim-Chester disease and nuclear medicine imaging. A case report and brief review

verfasst von: D. Bountas, M. Bountas, P. Exadactylou, C. Tziafalia, C. Dimitriadis, A. Doumas

Erschienen in: Skeletal Radiology | Ausgabe 2/2025

Einloggen, um Zugang zu erhalten

Abstract

Erdheim-Chester disease (ECD) is a rare clonal myeloid neoplasm typically affecting adults over 50 years old, with bone lesions in almost all patients. The prognosis is poor in most cases if left untreated. Clinical manifestations are not specific, which hinders early diagnosis. The disease has distinct radiological features. However, three-phase bone scintigraphy exhibits the most typical pattern of all imaging modalities, which is the prominent strikingly symmetrical radiotracer uptake in the distal ends of the femurs and proximal and distal ends of the tibiae, sparing the epiphyses. We report a case of a 54-year-old female patient, presenting with atypical persistent knee joint pain. After an MRI scan, she underwent a three-phase bone scan, revealing the characteristic pattern, thus indicating a possible ECD diagnosis, which was eventually confirmed in biopsy material. Novel aspects of the pathophysiology and treatment of the disease, as well as a differential diagnosis from the perspective of an MSK radiologist and nuclear medicine physician, are also discussed.
Literatur
2.
Zurück zum Zitat Jaffe HL. Lipid (Cholesterol) granulomatosis. Metabolic, degenerative, and inflammatory disease of bones and joints. 1972;535–41. Jaffe HL. Lipid (Cholesterol) granulomatosis. Metabolic, degenerative, and inflammatory disease of bones and joints. 1972;535–41.
4.
Zurück zum Zitat The WHO Classification of Tumours Editorial Board 2020 WHO Classification of Tumours Soft Tissue and Bone Tumours 3 5 IARC Press Lyon 337 499 The WHO Classification of Tumours Editorial Board 2020 WHO Classification of Tumours Soft Tissue and Bone Tumours 3 5 IARC Press Lyon 337 499
5.
Zurück zum Zitat Papo M, Emile JF, Maciel TT, Bay P, Baber A, Hermine O, et al. Erdheim-Chester disease: a concise review, vol. 21. Current Rheumatology Reports: Springer; 2019. Papo M, Emile JF, Maciel TT, Bay P, Baber A, Hermine O, et al. Erdheim-Chester disease: a concise review, vol. 21. Current Rheumatology Reports: Springer; 2019.
6.
Zurück zum Zitat Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood [Internet]. 2020 May 28;135(22):1929–45. Available from: https://doi.org/10.1182/blood.2019003507 Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood [Internet]. 2020 May 28;135(22):1929–45. Available from: https://​doi.​org/​10.​1182/​blood.​2019003507
7.
Zurück zum Zitat Starkebaum G, Hendrie P. Erdheim–Chester disease. Vol. 34, Best Practice and Research: Clinical Rheumatology. Bailliere Tindall Ltd; 2020. Starkebaum G, Hendrie P. Erdheim–Chester disease. Vol. 34, Best Practice and Research: Clinical Rheumatology. Bailliere Tindall Ltd; 2020.
8.
Zurück zum Zitat Kanakis M, Petrou P, Lourida G, Georgalas I. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective. Vol. 67, Survey of Ophthalmology. Elsevier Inc.; 2022. p. 388–410. Kanakis M, Petrou P, Lourida G, Georgalas I. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective. Vol. 67, Survey of Ophthalmology. Elsevier Inc.; 2022. p. 388–410.
9.
Zurück zum Zitat Yelfimov DA, Lightner DJ, Tollefson MK. Urologic manifestations of Erdheim-Chester disease. Urology. 2014;84(1):218–21.CrossRefPubMed Yelfimov DA, Lightner DJ, Tollefson MK. Urologic manifestations of Erdheim-Chester disease. Urology. 2014;84(1):218–21.CrossRefPubMed
10.
Zurück zum Zitat Estrada-Veras JI, O’Brien KJ, Boyd LC, Dave RH, Durham BH, Xi L, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357–66.CrossRefPubMedPubMedCentral Estrada-Veras JI, O’Brien KJ, Boyd LC, Dave RH, Durham BH, Xi L, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1(6):357–66.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood [Internet]. 2011 Mar 10;117(10):2783–90. Available from: https://doi.org/10.1182/blood-2010-10-313510 Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood [Internet]. 2011 Mar 10;117(10):2783–90. Available from: https://​doi.​org/​10.​1182/​blood-2010-10-313510
12.
Zurück zum Zitat Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M. The multifaceted anti-cancer effects of BRAF-inhibitors the wild type BRAF gene. Oncotarget [Internet]. 2019 [cited 2023 Aug 29];10(61):6623–40. Available from: www.oncotarget.com Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M. The multifaceted anti-cancer effects of BRAF-inhibitors the wild type BRAF gene. Oncotarget [Internet]. 2019 [cited 2023 Aug 29];10(61):6623–40. Available from: www.​oncotarget.​com
13.
Zurück zum Zitat Haroche J, Charlotte F, Arnaud L, Von Deimling A, Hélias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–3.CrossRefPubMed Haroche J, Charlotte F, Arnaud L, Von Deimling A, Hélias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–3.CrossRefPubMed
15.
Zurück zum Zitat Sun Z, Shen C. Differential diagnosis of rare diseases involving bilateral lower extremities with similar 99mTc-MDP bone scan patterns: analysis of a case series. Diagnostics (Basel). 2022 Apr 6;12(4). Sun Z, Shen C. Differential diagnosis of rare diseases involving bilateral lower extremities with similar 99mTc-MDP bone scan patterns: analysis of a case series. Diagnostics (Basel). 2022 Apr 6;12(4).
16.
Zurück zum Zitat Resnick D, Greenway G, Genant H, Brower A, Haghighi P, Emmett M. Erdheim-Chester disease. Radiology. 1982;142(2):289–95.CrossRefPubMed Resnick D, Greenway G, Genant H, Brower A, Haghighi P, Emmett M. Erdheim-Chester disease. Radiology. 1982;142(2):289–95.CrossRefPubMed
17.
Zurück zum Zitat Arnaud L, Malek Z, Archambaud F, Kas A, Toledano D, Drier A, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum. 2009;60(10):3128–38.CrossRefPubMed Arnaud L, Malek Z, Archambaud F, Kas A, Toledano D, Drier A, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum. 2009;60(10):3128–38.CrossRefPubMed
18.
19.
Zurück zum Zitat Ren G, Esposito M, Kang Y. Bone metastasis and the metastatic niche. J Mol Med (Berl). 2015;93(11):1203–12.CrossRefPubMed Ren G, Esposito M, Kang Y. Bone metastasis and the metastatic niche. J Mol Med (Berl). 2015;93(11):1203–12.CrossRefPubMed
20.
Zurück zum Zitat Khung S, Budzik JF, Amzallag-Bellenger E, Lambilliote A, Soto Ares G, Cotten A, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights Imaging. 2013;4(5):569–79.CrossRefPubMedPubMedCentral Khung S, Budzik JF, Amzallag-Bellenger E, Lambilliote A, Soto Ares G, Cotten A, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights Imaging. 2013;4(5):569–79.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Mosheimer BA, Oppl B, Zandieh S, Fillitz M, Keil F, Klaushofer K, et al. Bone involvement in Rosai-Dorfman disease (RDD): a case report and systematic literature review. Curr Rheumatol Rep. 2017;19(5):29.CrossRefPubMedPubMedCentral Mosheimer BA, Oppl B, Zandieh S, Fillitz M, Keil F, Klaushofer K, et al. Bone involvement in Rosai-Dorfman disease (RDD): a case report and systematic literature review. Curr Rheumatol Rep. 2017;19(5):29.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Demicco EG, Rosenberg AE, Björnsson J, Rybak LD, Unni KK, Nielsen GP. Primary Rosai-Dorfman disease of bone: a clinicopathologic study of 15 cases. Am J Surg Pathol. 2010;34(9):1324–33.CrossRefPubMed Demicco EG, Rosenberg AE, Björnsson J, Rybak LD, Unni KK, Nielsen GP. Primary Rosai-Dorfman disease of bone: a clinicopathologic study of 15 cases. Am J Surg Pathol. 2010;34(9):1324–33.CrossRefPubMed
23.
Zurück zum Zitat Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765.CrossRef Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765.CrossRef
24.
Zurück zum Zitat Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology. 2005;2005(1):373–6.CrossRef Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology. 2005;2005(1):373–6.CrossRef
25.
Zurück zum Zitat Durie BGM, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379–98.CrossRefPubMed Durie BGM, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379–98.CrossRefPubMed
26.
Zurück zum Zitat Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009;23(9):1545–56.CrossRefPubMed Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009;23(9):1545–56.CrossRefPubMed
27.
Zurück zum Zitat Shi XF, Hu SD, Li JM, Luo XF, Long ZB, Zhu Y, et al. Multimodal imaging and clinical characteristics of bone lesions in POEMS syndrome. Int J Clin Exp Med. 2015;8(5):7467–76.PubMedPubMedCentral Shi XF, Hu SD, Li JM, Luo XF, Long ZB, Zhu Y, et al. Multimodal imaging and clinical characteristics of bone lesions in POEMS syndrome. Int J Clin Exp Med. 2015;8(5):7467–76.PubMedPubMedCentral
29.
Zurück zum Zitat Behzadi AH, Raza SI, Carrino JA, Kosmas C, Gholamrezanezhad A, Basques K, et al. Applications of PET/CT and PET/MR imaging in primary bone malignancies. PET Clin. 2018;13(4):623–34.CrossRefPubMedPubMedCentral Behzadi AH, Raza SI, Carrino JA, Kosmas C, Gholamrezanezhad A, Basques K, et al. Applications of PET/CT and PET/MR imaging in primary bone malignancies. PET Clin. 2018;13(4):623–34.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Haroche J, Amoura Z, Dion E, Wechsler B, Costedoat-Chalumeau N, Cacoub P, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Vol. 83, Medicine. 2004. p. 371–92. Haroche J, Amoura Z, Dion E, Wechsler B, Costedoat-Chalumeau N, Cacoub P, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Vol. 83, Medicine. 2004. p. 371–92.
32.
Zurück zum Zitat Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood [Internet]. 2013 Feb 28;121(9):1495–500. Available from: https://doi.org/10.1182/blood-2012-07-446286 Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood [Internet]. 2013 Feb 28;121(9):1495–500. Available from: https://​doi.​org/​10.​1182/​blood-2012-07-446286
34.
Zurück zum Zitat Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, et al. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am J Hematol [Internet]. 2018 May 1;93(5):E114–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29396850. Accessed 6 Sept 2023 Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, et al. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. Am J Hematol [Internet]. 2018 May 1;93(5):E114–7. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​29396850. Accessed 6 Sept 2023
Metadaten
Titel
Erdheim-Chester disease and nuclear medicine imaging. A case report and brief review
verfasst von
D. Bountas
M. Bountas
P. Exadactylou
C. Tziafalia
C. Dimitriadis
A. Doumas
Publikationsdatum
06.06.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Skeletal Radiology / Ausgabe 2/2025
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-024-04718-z

Neu im Fachgebiet Radiologie

Ab sofort gelten die neuen Verordnungsausnahmen für Lipidsenker

Freie Fahrt für Lipidsenker? Das nicht, doch mit niedrigerem Schwellenwert fürs Infarktrisiko und neuen Indikationen hat der G-BA die Verordnungs-Handbremse ein gutes Stück weit gelockert.

Abdominale CT bei Kindern: 40% mit Zufallsbefunden

Wird bei Kindern mit stumpfem Trauma eine CT des Bauchraums veranlasst, sind in rund 40% der Fälle Auffälligkeiten zu sehen, die nichts mit dem Trauma zu tun haben. Die allerwenigsten davon sind klinisch relevant.

Genügt die biparametrische MRT für die Prostatadiagnostik?

Die multiparametrische Magnetresonanztomografie hat einen festen Platz im Screening auf klinisch signifikante Prostatakarzinome. Ob auch ein biparametrisches Vorgehen ausreicht, ist in einer Metaanalyse untersucht worden.

Höhere Trefferquoten bei Brustkrebsscreening dank KI?

Künstliche Intelligenz unterstützt bei der Auswertung von Mammografie-Screenings und senkt somit den radiologischen Arbeitsaufwand. Wie wirken sich diese Technologien auf die Trefferquote und die Falsch-positiv-Rate aus? Das hat jetzt eine Studie aus Schweden untersucht.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.